Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors, including nivolumab, are essential agents for treating non-small cell lung cancer. However, predictive markers are currently lacking, especially using factors based on patient-reported outcomes. METHODS: We conducted a prospective observational study of 244...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Yoh, Kiyotaka, Kato, Terufumi, Hosomi, Yukio, Usui, Kazuhiro, Fukui, Tomoya, Hirano, Katsuya, Tanaka, Hiroshi, Taguri, Masataka, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885731/
https://www.ncbi.nlm.nih.gov/pubmed/36300307
http://dx.doi.org/10.1093/jjco/hyac159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885731/
https://www.ncbi.nlm.nih.gov/pubmed/36300307
http://dx.doi.org/10.1093/jjco/hyac159

Ejemplares similares